May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Opticin Is an Inhibitor of VEGF–A and FGF–2–Activated Angiogenesis
Author Affiliations & Notes
  • M.M. Le Goff
    Wellcome Trust Centre for Cell–Matrix Research and The Medical School, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
  • M.A. Slevin
    Manchester Metropolitan University, Manchester, United Kingdom
  • P.N. Bishop
    Wellcome Trust Centre for Cell–Matrix Research and The Medical School, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
  • Footnotes
    Commercial Relationships  M.M. Le Goff, None; M.A. Slevin, None; P.N. Bishop, None.
  • Footnotes
    Support  The Wellcome Trust
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 451. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.M. Le Goff, M.A. Slevin, P.N. Bishop; Opticin Is an Inhibitor of VEGF–A and FGF–2–Activated Angiogenesis . Invest. Ophthalmol. Vis. Sci. 2005;46(13):451.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Opticin is a member of the small leucine–rich repeat protein/proteoglycan family. It is an extracellular matrix glycoprotein that is highly expressed in the eye throughout life and localises to the vitreous humour. The vitreous humour normally possesses anti–angiogenic properties to maintain its transparency. In this study we investigated whether opticin contributes to these properties. Methods: Recombinant bovine opticin was generated in 293–EBNA cells and purified from the conditioned media. The effects of opticin were tested on bovine aortic endothelial cells (BAEC) proliferation, migration and sprout formation stimulated by VEGF–A and FGF–2. Downstream signalling was analysed by semi–quantitative Western–blotting for phosphorylated ERK1/2. The effects of opticin on BAEC attachment, spreading and tubular formation were examined using a three dimensional type I collagen assay and VEGF–A, FGF–2 and bovine brain extract (BBE)–induced angiogenesis was performed to test the effects of opticin on in vivo chick choroiallantoic membrane (CAM) assay. Results: At 1 and 10 µg/ml, opticin had the ability to inhibit significantly both VEGF–A and FGF–2–stimulated proliferation, migration and sprout formation. The ERK1/2 phosphorylation downstream of VEGF–A and FGF–2 receptors was blocked by opticin. Opticin alone could disrupt attachment and spreading of BAEC on type I collagen matrix and blocked the BAEC attachment, spreading and tube–like structure formation stimulated by both VEGF–A and FGF–2. Opticin inhibited angiogenesis stimulated by VEGF–A, FGF–2 and BBE in the CAM assay. Conclusions: These results demonstrate that opticin has anti–angiogenic properties and inhibits the BAEC angiogenic responses to both VEGF–A and FGF–2 in in vitro cell culture systems. We also demonstrated that opticin inhibits angiogenesis in vivo. Opticin may play a key role in both the development of the eye (i.e. regression of the primary hyaloid vascular system) and in protection against vitreoretinal diseases such as proliferative diabetic retinopathy.

Keywords: extracellular matrix • vitreous • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×